DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
SENREBOTASE
2
Enzyme
Investigational
Unknown
Unknown
Neuralgia, Postherpetic; Urinary Bladder, Overactive
Unknown
SENREBOTASE
×
Maximum Phase:
2
First Approval:
None
UNII:
8SQP8A30GG
Molecule Type:
Enzyme
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SEPANTRONIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Prostatic Neoplasms
Unknown
SEPANTRONIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
7H5Q4J1CM5
Molecule Type:
Small molecule
Molecular Formula:
C20H19BrN4O3
Molecular Weight:
443.3
AlogP:
1.34
PSA:
77.96
HBD:
0.0
HBA:
#RotB:
5.0
Source:
VIDUPIPRANT
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
VIDUPIPRANT
×
Maximum Phase:
2
First Approval:
None
UNII:
61OTZ32XNC
Molecule Type:
Small molecule
Molecular Formula:
C28H27Cl2FN2O6S
Molecular Weight:
609.5
AlogP:
6.76
PSA:
121.8
HBD:
3.0
HBA:
#RotB:
9.0
Source:
FB-825
2
Unknown
Investigational
Unknown
Unknown
Dermatitis, Atopic
Unknown
FB-825
×
Maximum Phase:
2
First Approval:
None
UNII:
YO4XL7781V
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADELMIDROL
2
Small molecule
Investigational
Unknown
Unknown
Vaginitis
Unknown
ADELMIDROL
×
Maximum Phase:
2
First Approval:
None
UNII:
1BUC3685QU
Molecule Type:
Small molecule
Molecular Formula:
C13H26N2O4
Molecular Weight:
274.36
AlogP:
-0.07
PSA:
98.66
HBD:
4.0
HBA:
#RotB:
12.0
Source:
INCYCLINIDE
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Neoplasms
Unknown
INCYCLINIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
21G64WZQ4I
Molecule Type:
Small molecule
Molecular Formula:
C19H17NO7
Molecular Weight:
371.35
AlogP:
0.58
PSA:
158.15
HBD:
5.0
HBA:
#RotB:
1.0
Source:
SITAFLOXACIN
2
Small molecule
Investigational
Unknown
Unknown
Bacterial Infections
Bacterial DNA gyrase inhibitor
SITAFLOXACIN
×
Maximum Phase:
2
First Approval:
None
UNII:
45IP57B62B
Molecule Type:
Small molecule
Molecular Formula:
C19H18ClF2N3O3
Molecular Weight:
409.82
AlogP:
2.7
PSA:
88.56
HBD:
2.0
HBA:
#RotB:
3.0
Source:
VILOBELIMAB
2
Antibody
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Inflammation; Microscopic Polyangiitis; Pyoderma; Scleroderma, Systemic; Sepsis; Severe Acute Respiratory Syndrome; Shock, Septic
Complement C5 inhibitor
VILOBELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FOSMANOGEPIX
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Candidemia; Mycoses
GPI-anchored wall transfer protein 1 inhibitor
FOSMANOGEPIX
×
Maximum Phase:
2
First Approval:
None
UNII:
1XQ871489P
Molecule Type:
Small molecule
Molecular Formula:
C22H21N4O6P
Molecular Weight:
468.41
AlogP:
2.21
PSA:
147.64
HBD:
2.0
HBA:
#RotB:
9.0
Source:
LY-2606368
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Ovarian Neoplasms
Serine/threonine-protein kinase Chk1 inhibitor
LY-2606368
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FALLYPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Obesity, Morbid; Obesity
Unknown
FALLYPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
G9FWZ369GX
Molecule Type:
Small molecule
Molecular Formula:
C20H29FN2O3
Molecular Weight:
364.46
AlogP:
2.99
PSA:
50.8
HBD:
1.0
HBA:
#RotB:
10.0
Source:
E-7016
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Melanoma
Unknown
E-7016
×
Maximum Phase:
2
First Approval:
None
UNII:
M8926C7ILX
Molecule Type:
Small molecule
Molecular Formula:
C20H19N3O3
Molecular Weight:
349.39
AlogP:
2.65
PSA:
78.45
HBD:
2.0
HBA:
#RotB:
2.0
Source:
ATOPAXAR
2
Small molecule
Investigational
Unknown
Unknown
Acute Coronary Syndrome; Coronary Disease
Proteinase-activated receptor 1 antagonist
ATOPAXAR
×
Maximum Phase:
2
First Approval:
None
UNII:
HTI275SD2D
Molecule Type:
Small molecule
Molecular Formula:
C29H38FN3O5
Molecular Weight:
527.64
AlogP:
4.79
PSA:
84.32
HBD:
1.0
HBA:
#RotB:
9.0
Source:
PERPHENAZINE 4-AMINOBUTYRATE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Unknown
PERPHENAZINE 4-AMINOBUTYRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
K1WO7H97QZ
Molecule Type:
Small molecule
Molecular Formula:
C25H33ClN4O2S
Molecular Weight:
489.09
AlogP:
4.23
PSA:
62.04
HBD:
1.0
HBA:
#RotB:
10.0
Source:
ABX-464
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; HIV Infections; Severe Acute Respiratory Syndrome
Cap binding complex modulator
ABX-464
×
Maximum Phase:
2
First Approval:
None
UNII:
26RU378B9V
Molecule Type:
Small molecule
Molecular Formula:
C16H10ClF3N2O
Molecular Weight:
338.72
AlogP:
5.53
PSA:
34.15
HBD:
1.0
HBA:
#RotB:
3.0
Source:
DKN-01
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Biliary Tract Neoplasms
Dickkopf-related protein 1 inhibitor
DKN-01
×
Maximum Phase:
2
First Approval:
None
UNII:
RM898LZ4SI
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMILOMOTIDE
2
Protein
Investigational
Unknown
Unknown
Alzheimer Disease
Unknown
AMILOMOTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
31830Y299X
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABT-072
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
ABT-072
×
Maximum Phase:
2
First Approval:
None
UNII:
PSQ4R5K1QI
Molecule Type:
Small molecule
Molecular Formula:
C24H27N3O5S
Molecular Weight:
469.56
AlogP:
3.37
PSA:
110.26
HBD:
2.0
HBA:
#RotB:
6.0
Source:
FROVOCIMAB
2
Antibody
Investigational
Unknown
Unknown
Hyperlipidemias; Hypercholesterolemia
Subtilisin/kexin type 9 inhibitor
FROVOCIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
87PZ955YRB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RAF-265
2
Small molecule
Investigational
Unknown
Unknown
Melanoma; Neoplasms
Serine/threonine-protein kinase B-raf inhibitor
RAF-265
×
Maximum Phase:
2
First Approval:
None
UNII:
8O434L3768
Molecule Type:
Small molecule
Molecular Formula:
C24H16F6N6O
Molecular Weight:
518.42
AlogP:
6.93
PSA:
80.65
HBD:
2.0
HBA:
#RotB:
5.0
Source:
BALTALEUCEL-T
2
Cell
Investigational
Unknown
Unknown
Lymphoma
Unknown
BALTALEUCEL-T
×
Maximum Phase:
2
First Approval:
None
UNII:
F9670LP52I
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-06459988
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
PF-06459988
×
Maximum Phase:
2
First Approval:
None
UNII:
5IE92SK9EB
Molecule Type:
Small molecule
Molecular Formula:
C19H22ClN7O3
Molecular Weight:
431.88
AlogP:
2.13
PSA:
110.19
HBD:
2.0
HBA:
#RotB:
7.0
Source:
GTS-21
2
Small molecule
Investigational
Unknown
Unknown
Autistic Disorder; Obesity; Alzheimer Disease; Psychotic Disorders; Schizophrenia; Tobacco Use Disorder
Unknown
GTS-21
×
Maximum Phase:
2
First Approval:
None
UNII:
8S399XDN2K
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O2
Molecular Weight:
308.38
AlogP:
3.77
PSA:
43.71
HBD:
0.0
HBA:
#RotB:
4.0
Source:
RISLENEMDAZ
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
RISLENEMDAZ
×
Maximum Phase:
2
First Approval:
None
UNII:
5HAM167S5T
Molecule Type:
Small molecule
Molecular Formula:
C19H23FN4O2
Molecular Weight:
358.42
AlogP:
3.19
PSA:
67.35
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TEZAMPANEL
2
Small molecule
Investigational
Unknown
Unknown
Migraine Disorders
Glutamate receptor ionotropic AMPA antagonist
TEZAMPANEL
×
Maximum Phase:
2
First Approval:
None
UNII:
GA36S2O9C2
Molecule Type:
Small molecule
Molecular Formula:
C13H21N5O2
Molecular Weight:
279.34
AlogP:
0.61
PSA:
103.79
HBD:
3.0
HBA:
#RotB:
4.0
Source:
DM-CHOC-PEN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DM-CHOC-PEN
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DALOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Multiple Myeloma; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neuroendocrine Tumors; Rectal Neoplasms
Insulin-like growth factor I receptor antagonist
DALOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6YI1L648RH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CGC-11047
2
Small molecule
Investigational
Unknown
Unknown
Macular Degeneration; Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
CGC-11047
×
Maximum Phase:
2
First Approval:
None
UNII:
2C4Y86R2AX
Molecule Type:
Small molecule
Molecular Formula:
C14H32N4
Molecular Weight:
256.44
AlogP:
0.72
PSA:
48.12
HBD:
4.0
HBA:
#RotB:
14.0
Source:
KALLIKREIN-1
2
Unknown
Investigational
Unknown
Unknown
Stroke; Cerebrovascular Disorders; Ischemic Stroke
Unknown
KALLIKREIN-1
×
Maximum Phase:
2
First Approval:
None
UNII:
JNG5AC5YGW
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REZATOMIDINE
2
Small molecule
Investigational
Unknown
Unknown
Cystitis, Interstitial; Diabetic Neuropathies; Fibromyalgia; Irritable Bowel Syndrome
Unknown
REZATOMIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
W5LMZ0RC8I
Molecule Type:
Small molecule
Molecular Formula:
C13H16N2S
Molecular Weight:
232.35
AlogP:
3.84
PSA:
31.58
HBD:
2.0
HBA:
#RotB:
2.0
Source:
GISADENAFIL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Erectile Dysfunction; Prostatic Hyperplasia; Urinary Bladder, Overactive
Phosphodiesterase 5A inhibitor
GISADENAFIL
×
Maximum Phase:
2
First Approval:
None
UNII:
S6G4R7DI1C
Molecule Type:
Small molecule
Molecular Formula:
C23H33N7O5S
Molecular Weight:
519.63
AlogP:
1.12
PSA:
135.54
HBD:
1.0
HBA:
#RotB:
10.0
Source:
AV-101
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Depressive Disorder; Depressive Disorder, Major
Glutamate [NMDA] receptor antagonist
AV-101
×
Maximum Phase:
2
First Approval:
None
UNII:
77XLH9L40B
Molecule Type:
Small molecule
Molecular Formula:
C10H11ClN2O3
Molecular Weight:
242.66
AlogP:
0.91
PSA:
106.41
HBD:
3.0
HBA:
#RotB:
4.0
Source:
FISPEMIFENE
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Hypogonadism; Sexual Dysfunction, Physiological
Estrogen receptor modulator
FISPEMIFENE
×
Maximum Phase:
2
First Approval:
None
UNII:
3VZ2833V08
Molecule Type:
Small molecule
Molecular Formula:
C26H27ClO3
Molecular Weight:
422.95
AlogP:
5.66
PSA:
38.69
HBD:
1.0
HBA:
#RotB:
11.0
Source:
ORP-101
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Kappa opioid receptor antagonist
ORP-101
×
Maximum Phase:
2
First Approval:
None
UNII:
SE6KE496VO
Molecule Type:
Small molecule
Molecular Formula:
C60H84N2O8
Molecular Weight:
961.34
AlogP:
9.19
PSA:
102.32
HBD:
2.0
HBA:
#RotB:
13.0
Source:
ZALUNFIBAN
2
Small molecule
Investigational
Unknown
Unknown
Coronary Disease; ST Elevation Myocardial Infarction
Unknown
ZALUNFIBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
5XQC91CO1F
Molecule Type:
Small molecule
Molecular Formula:
C16H18N8O2S
Molecular Weight:
386.44
AlogP:
-0.48
PSA:
130.54
HBD:
3.0
HBA:
#RotB:
4.0
Source:
1
2
…
161
162
163
164
165
166
167
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA